Corpus ID: 36174877

[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans].

@article{MartinnTorres2004RecombinantHA,
  title={[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans].},
  author={Federico Martin{\'o}n-Torres and J M Iglesias Meleiro and M Fern{\'a}ndez Sanmart{\'i}n and Antonio Rodr{\'i}guez N{\'u}{\~n}ez and J Mar{\'i}a Martin{\'o}n S{\'a}nchez},
  journal={Anales de pediatria},
  year={2004},
  volume={61 3},
  pages={
          261-5
        }
}
Meningococcal purpura fulminans (MPF) produces high mortality and morbidity, despite appropriate standard therapy. Administration of recombinant human activated protein C (rhAPC) has been successfully applied in adults with MPF and pediatric studies are under way. We report three pediatric patients with MPF treated with rhAPC as compassionate therapy. In two of these patients, positive clinical and laboratory effects were observed and both children achieved full recovery. The remaining patient… Expand
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies
TLDR
Drot AA-treated adult patients with severe sepsis presenting with PF/MEN/MD had a similar SBE rate, a lower observed 28-day mortality rate, and a higher observed rate of ICH than DrotAA-treated patients without PF/ MEN/MD. Expand
Protéine C activée, oui, non, quand ? Activated protein C: yes or no but when?
TLDR
Treatment with activated protein C made doctors thinking about a more global therapy about severe sepsis, in order to improve quality of care and to make possible an early implementation of well designed therapeutic protocols. Expand